614-02-8

Basic information

• Product Name: N⁶-[(benzyloxy)carbonyl]-N²-{N ²,N⁶-bis[(benzyloxy)carbonyl]-L-lysyl}-L-lysine
• Synonyms: N⁶-[(benzyloxy)carbonyl]-N²-{N ²,N⁶-bis[(benzyloxy)carbonyl]-L-lysyl}-L-lysine
• CAS NO: 614-02-8
• Molecular Weight: 676.767
• Mol File: 614-02-8.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: N⁶-[(benzyloxy)carbonyl]-N²-{N ²,N⁶-bis[(benzyloxy)carbonyl]-L-lysyl}-L-lysine(CAS DataBase Reference)
• NIST Chemistry Reference: N⁶-[(benzyloxy)carbonyl]-N²-{N ²,N⁶-bis[(benzyloxy)carbonyl]-L-lysyl}-L-lysine(614-02-8)
• EPA Substance Registry System: N⁶-[(benzyloxy)carbonyl]-N²-{N ²,N⁶-bis[(benzyloxy)carbonyl]-L-lysyl}-L-lysine(614-02-8)

Safety Data

• Hazardous Substances Data: 614-02-8(Hazardous Substances Data)

Upstream product

• 13523-84-7 N⁶-benzyloxycarbonyl-N²-(N²,N⁶-bis-benzyloxycarbonyl-L-lysyl)-D-lysine methyl ester 
• 52123-30-5 N²-L-lysyl-L-lysine dihydrochloride 
• 31139-36-3 dibenzyl dicarbonate 
• 13184-13-9 dilysine 
• 13795-24-9 benzyl 4-nitrophenyl carbonate 
• 501-53-1 benzyl chloroformate 
• 1155-64-2 N₆-[(benzyloxy)carbonyl]-L-lysine 
• 27894-50-4 methyl (2S)-2-amino-6-{[(benzyloxy)carbonyl]amino}hexanoate hydrochloride 
• 24498-31-5 (S)-methyl 2-amino-6-(benzyloxycarbonylamino)hexanoate 
• 405-39-0 N,N'-di-[(phenylmethoxy)carbonyl]-L-lysine 
• 13523-84-7 N^α,N^ε-Bis(benzyloxycarbonyl)-L-lysyl-N^ε-(benzyloxycarbonyl)-L-lysine Methyl Ester 

Downstream Products

• 122701-29-5 N⁶-benzyloxycarbonyl-N²-[N⁶-benzyloxycarbonyl-N²-(N²,N⁶-bis-benzyloxycarbonyl-L-lysyl)-L-lysyl]-L-lysine methyl ester 
• 1346119-11-6 C₆₅H₁₀₁N₇O₁₀ 
• 120207-81-0 N⁶-benzyloxycarbonyl-N²-[N⁶-benzyloxycarbonyl-N²-(N²,N⁶-bis-benzyloxycarbonyl-L-lysyl)-L-lysyl]-L-lysine 

Relevant articles and documents

GLUCOSE-RESPONSIVE INSULIN CONJUGATES

Glucose-responsive insulin conjugates that contain one or more linear oligomer sugar cluster are provided. Such insulin conjugates that may display a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose, even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule.

CONJUGATES COMPRISING PEPTIDE GROUPS AND METHODS RELATED THERETO

In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and at least two of the active agents are covalently coupled to side chains of the amino acids. The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY

Here described are compounds of formula I: wherein R1 and R2 is independently selected from a group consisting of C10 to C18 alkyl, C12 to C18 alkenyl, and oleyl group; wherein R3 and R4 are independently selected from a group consisting of C1 to C6 alkyl, and C2 to C6 alkanol; wherein X is selected from a group consisting of -CH2-, -S-, and -O- or absent; wherein Y is selected from -(CH2)n, -S(CH2)n, -O(CH2)n-, thiophene, -SO2(CH2)n-, and ester, wherein n = 1 -4; wherein a = 1 -4; wherein b=l -4; wherein c=l-4; and wherein Z is a counterion; and compounds consisting of the structure (targeting molecule)m-linker-(targeting molecule)n, wherein the targeting molecule is a retinoid or a fat soluble vitamin having a specific receptor on the target cell; wherein m and n are independently 0, 1, 2 or 3; and wherein the linker comprises a polyethylene glycol (PEG) or PEG-like molecule, as well as compositions and pharmaceutical formulations including one or both of these compounds which are useful for the delivery of therapeutic agents; and methods of using these compositions and pharmaceutical formulations.